Vue normale

F.D.A. Panel’s Vote on Peptides Raises Concerns About a Prescribing Boom

24 juillet 2026 à 17:15
The committee endorsed broader use of the peptides in lightly regulated compounding pharmacies that have grown into a multibillion-dollar business.

© Andrew Mangum for The New York Times

Some F.D.A. scientists pointed out that the peptides under review had not been proven to be safe or effective, and could present risks to patients.

With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access

24 juillet 2026 à 06:45
Companies in Africa and India will make generic versions of the pill that could cost as little as $5 per person per year. But access to the drug and other new products in much of Latin America remains uncertain.

© Arlette Bashizi for The New York Times

Health workers speaking with students about H.I.V. prevention drugs at the University of Zambia in Lusaka in March.

With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access

24 juillet 2026 à 06:45
Companies in Africa and India will make generic versions of the pill that could cost as little as $5 per person per year. But access to the drug and other new products in much of Latin America remains uncertain.

© Arlette Bashizi for The New York Times

Health workers speaking with students about H.I.V. prevention drugs at the University of Zambia in Lusaka in March.
❌